|
Palo Alto, CA, - June 2, 2005 – Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate update at the Pacific Growth Equities Life Sciences Growth conference in San Francisco on Tuesday, June 7, 2005 at 10:00 am Pacific time (1:00 pm Eastern time). A live webcast of the presentation will be available on the Telik website, www.telik.com. An archived webcast will be accessible on the Telik site through June 14, 2005.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate. Three Phase 3 registration trials with TELCYTA are in progress in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
